World Fair for Organic Wines: the Trade Fair Will Be Back Again in Force In 2022!
Millésime Bio has become, over the years, the number one marketplace for professionals in the organic wine, cider, beer and spirits industries. With its digital session on 17 and 18 January 2022 and its physical fair on 24, 25 and 26 January 2022 at Montpellier Exhibition Centre, the World Fair for Organic Wines will be the first major international wine fair since the COVID crisis, a symbol that the recovery is underway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005696/en/
(Photo: Gilles Lefrancq/Millésime Bio)
MILLESIME BIO 2022: A DOUBLE EVENT
Millésime Bio, traditionally the first wine, cider, beer and spirits trade fair of the year, will take place in two stages for this 2022 edition. A double event that will guarantee all professionals their participation while taking into account the sanitary constraints imposed in France and abroad.
The World fair for organic wines will start on 17 January for two days. Based on the model of the 2021 100% digital edition, more than 450 exhibitors and several thousand visitors will be able to exchange information and make initial contacts prior to the physical fair. On this occasion, visitors will discover in preview the medal-winners list of the Challenge Millésime Bio 2022 contest. From Monday 24 January to Wednesday 26 January, the physical fair will be an opportunity to get back to live tastings and meetings.
12/01/2022 - CHALLENGE MILLESIME BIO 2022
Every year, SudVinBio organises the largest international organic wine contest before the fair: the Challenge Millésime Bio contest. This year, the 15th edition of the contest will take place on Wednesday 12 January 2022.
NEW: Challenge Millésime Bio is opening up to international organic beers. The contest team will be accompanied by the SNBI (French National Union for Independent Breweries) to set up this tasting.
The medal-winning wines and beers will be available for tasting during the 3 days of the fair, in an area dedicated to the Challenge Millésime Bio.
More than 1,400 exhibitors from 20 countries will be there, in the heart of the number one organic vineyard in France, and will present about 40% of the French organic wine offer and a wide range of the international offer. This renewed enthusiasm consolidates Millésime Bio's position as the key marketplace that will set the trend for future trade fairs in a post health crisis context.
In parallel with the meetings with exhibitors, visitors will be able to attend a 2-day programme of conferences and Master Classes led by experts. The programme will include the results of a European IPSOS/Millésime Bio study on organic wine consumption habits.
"The Millésime Bio trade fair will welcome you from 17 January, to start with in its digital format. Following the success of last year's launch, we have perfected our online platform this year, in order to programme it a few days before our traditional physical event, which is back at last!
More than ever, we are listening to visitors and exhibitors to optimise the efficiency of this key event for buyers in the organic wine and spirits sector. Thus, a special place is reserved this year for the brewery and cider industries.”
Jeanne Fabre, President of the Millésime Bio Commission
ABOUT
MILLÉSIME BIO IS ORGANISED BY SUDVINBIO, OCCITANIA TRADE ASSOCIATION OF ORGANIC VINTNERS
SudVinBio is a non-profit association created in 1991. It is an interprofessional organisation representing producers (independent wineries and cooperatives) and merchants of organic wines in the Occitania region, France’s number one organic wine region. SudVinBio represents around 70% of the regional production of certified organic wines at the end of 2020 (around 700 000 hl). It orchestrates promotional and communication activities, protects the interests of its members, provides support for research and development as well as advisory services to its members.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005696/en/
Contact information
PRESS CONTACT
Anaïs Marchand & Fanny Courtial
+33 (0)4 72 07 42 41
fanny.courtial@clairdelune.fr – www.clairdelune.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom